Botox under the eyes: lower-lid wrinkles are not crow's-feet
Botox Cosmetic's lateral-canthal-line approval does not cover all lower-eyelid wrinkles. Small lower-lid studies do not settle individual suitability; a consultation should distinguish moving creases, skin texture, bags, and eye-surface function.
Botox Cosmetic is FDA approved for temporary improvement of moderate to severe lateral canthal lines associated with orbicularis oculi activity in adults. Those lines are beside the eye. A proposal to inject the lower eyelid for under-eye wrinkles is a different, off-label anatomical question, and small published studies do not turn it into an FDA-approved indication.123
The phrase “under-eye wrinkle” can refer to several different structures. A fine crease that appears during a smile, a line visible at rest, crinkled skin texture, a hollow, a raised bag, and a shadow cast by cheek anatomy do not have the same mechanism. Before discussing an injection, ask the clinician to identify which of those findings is actually being targeted.
Draw the boundary at the lateral canthus
Crow’s-feet radiate from the outside corner of the eye. The lower eyelid extends beneath the lashes toward the cheek. Both regions involve nearby muscles, but the approved lateral-canthal-line indication does not automatically cover lower-eyelid placement.1 The crow’s-feet guide owns that labeled smile-line endpoint; this article stays with the lower-lid decision.
| Visible concern | Question the clinician must answer | Why Botox may miss the goal |
|---|---|---|
| Side-eye smile crease | Is it a lateral canthal line within the named label? | The treatment region may be beside, not beneath, the eye |
| Lower-lid moving fold | What evidence and eye-function assessment support this off-label site? | The lower lid has a different functional margin |
| Resting line | How much is muscle movement versus skin structure? | Reducing movement may not erase a fixed crease |
| Hollow, bag or shadow | Is the concern volume, fat position, swelling, or surface texture? | Toxin does not add volume or move a bag |
An under-eye quote should identify the precise anatomy, not offer “crow’s-feet plus a little below” as an undefined extension. The exact product matters too: a study or label for BOTOX Cosmetic cannot be silently transferred to every toxin formulation.
What the lower-lid studies can establish
Small historical studies explored lower-eyelid botulinum toxin for selected cosmetic goals.23 Their limited size and protocols can show that the question has been studied; they cannot establish a broad population-wide risk rate, a standard dose, superiority over other methods, or a guarantee for a person with different lid position or eye-surface history. They also cannot create an FDA indication.
Ask whether the proposed clinician relies on an exact lower-lid study or on experience, and whether the study’s population, target wrinkle, product, follow-up and adverse-event collection match the plan. “We have done it many times” may be relevant experience, but it is not a substitute for specifying what happened, what could go wrong, and how the result would be assessed.
Preserve blinking and eye-surface context
The lower lid helps maintain the tear film and works with blinking. A person with existing dry eye, incomplete lid closure, lid laxity, previous eye surgery, contact-lens difficulty, or a history of eyelid weakness has information the injector needs before deciding whether to propose any treatment. The FDA label includes warnings about toxin effects beyond the intended site and about pre-existing conditions at injection sites.1
This is a functional assessment, not an online exclusion list. Record what the eyelids do when the person blinks and closes the eyes, and what symptoms existed beforehand. If dryness or unusual blinking appears after an injection, the dry-eye assessment guide explains why the symptom deserves a specific evaluation rather than an assumption about cosmetic lines. Separately, the FDA label says new trouble swallowing, speaking, or breathing after treatment needs immediate medical attention; do not treat those as routine dry-eye symptoms.1
Compare the intended endpoint with the alternative
If the concern is a hollow, ask whether the infraorbital filler indication is relevant to the exact finding and product. If it is skin texture, a clinician may discuss a skin-directed approach. If it is a bag or structural lid issue, a different specialist may be appropriate. Those paths have their own evidence and risks; none should be sold as a default correction for every under-eye photograph.
Bring neutral and smiling photographs in the same light. Ask the provider to mark the specific crease, state whether the planned use is on or off label, document baseline lid and tear-surface function, define what improvement would count, and explain the response route for visual, lid, or eye-surface symptoms. A precise answer can also be that Botox is not the tool for the finding shown.
Sources
- U.S. Food and Drug Administration. BOTOX Cosmetic prescribing information. Exact adult lateral-canthal-line indication; no general lower-eyelid wrinkle indication; boxed warning calls for immediate care for swallowing, speech, or breathing problems. Accessed .
- PubMed. Botulinum A toxin in the lower eyelid: dose-finding study. Small original lower-lid study, useful for the limited nature of off-label evidence, not a protocol or population-wide outcome claim. Accessed .
- PubMed. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Additional small historical lower-lid report; not an FDA indication or modern comparative trial. Accessed .